BioMed Research International

Research Article

Effects of Neurodynamic Mobilization on Health-Related Quality of Life and Cervical Deep Flexors Endurance in Patients of Cervical Radiculopathy: A Randomized Trial

Table 2

Comparison of craniocervical flexion test and 8 domains of SF 36 within the control group.


Variable	—	Interquartile range	Mean rank^a	Chi-square (), value^a	Post hoc analysis	score^b	value^b

Craniocervical flexion (mmHg)	Base line	22 (20 to 24)	1.18	68.70,	Pre and midtreatment	-5.26	<0.017
	After 2^nd week	23 (22 to 26)	2.09		Mid and posttreatment	-4.66	<0.017
	After 4^th week	24 (24 to 26)	2.73		Pre and posttreatment	-5.53	<0.017
Physical functioning–SF36	Baseline	40 (21.25 to 55)	1.41	54.25,	Pre and midtreatment	-3.17	0.001
	After 2^nd week	52.5 (30 to 65)	1.86		Mid and posttreatment	-5.03	<0.017
	After 4^th week	70 (45 to 80)	2.73		Pre and posttreatment	-4.66	<0.017
Role limitation due to physical health–SF36	Baseline	0 (0 to 0)	1.63	37.90,	Pre and midtreatment	-2.55	0.011
	After 2^nd week	0 (0 to 25)	1.88		Mid and posttreatment	-4.11	<0.017
	After 4^th week	50 (0 to 75)	2.50		Pre and posttreatment	-4.45	<0.017
Role limitation due to emotional problem–SF36	Baseline	16.65 (0 to 66.70)	1.88	17.03,	Pre and midtreatment	-1.41	0.157
	After 2^nd week	16.65 (0 to 66.70)	1.92		Mid and posttreatment	-2.75	<0.017
	After 4^th week	66.70 (0 to 100)	2.20		Pre and posttreatment	-2.88	<0.017
Energy/fatigue–SF36	Baseline	42.5 (35 to 50)	1.42	48.42,	Pre and midtreatment	-4.01	<0.017
	After 2^nd week	45 (36.25 to 55)	1.94		Mid and posttreatment	-4.47	<0.017
	After 4^th week	55 (45 to 63.75)	2.64		Pre and posttreatment	-4.93	<0.017
Emotional wellbeing–SF36	Baseline	52 (40 to 56)	1.61	27.22,	Pre and midtreatment	-2.64	<0.017
	After 2^nd week	52 (40 to 60)	1.92		Mid and posttreatment	-4.04	<0.017
	After 4^th week	60 (48 to 60)	2.47		Pre and posttreatment	-4.13	<0.017
Social functioning–SF36	Baseline	50 (37.5 to 62.5)	1.63	35.89,	Pre and midtreatment	-2.44	0.015
	After 2^nd week	50 (37.5 to 62.5)	1.85		Mid and posttreatment	-4.37	<0.017
	After 4^th week	62.5 (50 to 75)	2.52		Pre and posttreatment	-4.45	<0.017
Pain–SF36	Baseline	45 (45 to 45)	1.45	54.60,	Pre and midtreatment	-3.37	<0.017
	After 2^nd week	45 (45 to 67.5)	1.83		Mid and posttreatment	-4.45	<0.017
	After 4^th week	55 (55 to 77.5)	2.72		Pre and posttreatment	-5.13	<0.017
General health perception–SF36	Base line	35 (31.25 to 45)	1.41	51.95,	Pre and midtreatment	-3.64	<0.017
	After 2^nd week	40 (35 to 50)	1.92		Mid and posttreatment	-4.58	<0.017
	After 4^th week	47.5 (40 to 60)	2.67		Pre and posttreatment	-5.01	<0.017